Clinical trial
An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00249353 is registered in ClinicalTrials.gov with McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2002
- Completion date
- October 31, 2002
- Enrollment
- 220 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.